AACR Names Dr. Timothy Yap as Editor-in-Chief of the Journal Clinical Cancer Research
PHILADELPHIA – The American Association for Cancer Research (AACR) today announced the appointment of Timothy A. Yap, MBBS, PhD, as...
Search/Filter
Loading...
AACR Statement and Call to Action Regarding the Administration’s Recent Actions Affecting NIH and the American People
The American Association for Cancer Research (AACR) is deeply concerned that the Administration’s recent actions are threatening the National...
Radiation Plus Combination Immunotherapy May Help Preserve Bladder in Some Patients With Muscle-invasive Bladder Cancer
PHILADELPHIA – Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab...
Dr. Daniel Nomura Selected as Editor-in-Chief of the AACR Journal Molecular Cancer Therapeutics
PHILADELPHIA – The American Association for Cancer Research (AACR) today announced the appointment of Daniel K. Nomura, PhD, as editor-in-chief...
AACR Recognizes World Cancer Day on February 4
PHILADELPHIA – The American Association for Cancer Research (AACR) today joins individuals and organizations around the world in recognizing...
AACR Statement on the New Administration’s Recent Executive Orders and Policy Proposals
The American Association for Cancer Research (AACR) is increasingly concerned about the numerous executive orders and policy proposals that...
A Therapeutic HPV Vaccine Could Eliminate Precancerous Cervical Lesions
PHILADELPHIA – A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according...
AACR Expresses Sincere Appreciation to NIH Director Monica M. Bertagnolli, MD
PHILADELPHIA — The American Association for Cancer Research (AACR) today expressed its gratitude to Monica M. Bertagnolli, MD, for...
ZEST Trial Offers Insights for Using ctDNA to Predict Breast Cancer Recurrence
The study was terminated early due to low detection of ctDNA after treatment among patients with stage 1 to...
HR-positive, HER2-negative Breast Cancer Patients With High Risk of Recurrence May Benefit From Addition of Anthracyclines to Taxane- based Chemotherapy
Genomic testing helped identify which patients with node-negative, HR-positive, HER2- negative breast cancer could benefit from the addition of...